Andiappan Murugan

Title: The Innovative Contributions of Andiappan Murugan

Introduction

Andiappan Murugan is a notable inventor based in Bengaluru, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target mutated forms of the epidermal growth factor receptor (EGFR). With a total of four patents to his name, Murugan's work is paving the way for advancements in cancer treatment.

Latest Patents

Murugan's latest patents focus on 2-(2,4,5-substituted-anilino)pyrimidine compounds. These compounds and their pharmaceutically acceptable salts are designed to treat or prevent diseases mediated by specific mutated forms of EGFR, such as the L858R activating mutant, the Exon19 deletion activating mutant, and the T790M resistance mutant. The invention also encompasses pharmaceutical compositions that include these compounds, especially useful polymorphic forms, intermediates for manufacturing, and methods for treating diseases associated with various EGFR mutations.

Career Highlights

Throughout his career, Andiappan Murugan has worked with prominent companies in the pharmaceutical industry, including AstraZeneca. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Murugan has collaborated with notable professionals in his field, including Sam Butterworth and Maurice Raymond Verschoyle Finlay. These collaborations have likely enriched his research and development efforts.

Conclusion

Andiappan Murugan's innovative work in the pharmaceutical sector, particularly in developing targeted cancer therapies, showcases his commitment to advancing medical science. His contributions are significant in the ongoing fight against cancer and highlight the importance of innovation in healthcare.